- 30/08/2023Risk assessment of chemical mixtures [59:58]206VN3-5502-2023-2024-08-30
- 30/08/2023Risk assessment of chemical mixtures [1:59:53]81VN3-5502-2023-2024-08-30-A
- 30/08/2023Risk assessment of chemical mixtures [59:53]81VN3-5502-2023-2024-08-30-B
- 30/08/2023Risk assessment of chemical mixtures [1:59:59]70VN3-5502-2023-2024-08-30-C
- 30/08/2023Risk assessment of chemical mixtures [1:59:53]81VN3-5502-2023-2024-08-30-D
- 31/08/2023Risk assessment of chemical mixtures [1:59:57]65VN3-5502-2023-2024-08-31
- 31/08/2023Risk assessment of chemical mixtures [1:59:52]70VN3-5502-2023-2024-08-31-A
- 31/08/2023Risk assessment of chemical mixtures [59:57]74VN3-5502-2023-2024-08-31-B
- 31/08/2023Risk assessment of chemical mixtures [44:53]61VN3-5502-2023-2024-08-31-C
- 31/08/2023Risk assessment of chemical mixtures [59:59]60VN3-5502-2023-2024-08-31-D
- 31/08/2023Risk assessment of chemical mixtures [59:53]69VN3-5502-2023-2024-08-31-E
- 01/09/2023Risk assessment of chemical mixtures [59:59]68VN3-5502-2023-2024-09-01
- 01/09/2023Risk assessment of chemical mixtures [1:59:53]64VN3-5502-2023-2024-09-01-A
- 01/09/2023Module 8 Human pharmaceuticals - Dr Hasan Mohajeri-GMT2023-09-01T06:17:26Z [3:38:22]77VN3-5502-2023-2024-09-01-B
- 01/09/2023Risk assessment of chemical mixtures [59:59]60VN3-5502-2023-2024-09-01-C